Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C
Clinical trial NCT03531905 · COMPLETED
Trial details
- NCT number
- NCT03531905
- Sponsor
- Esperion Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-05-09
- Primary completion
- 2019-06-18
- Enrollment
- 242
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.